drugset
drugset / Trial / NCT05085626

Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer

NCT05085626 ↗

Phase 2 Unknown 40 enrolled Tianjin Medical University Cancer Institute and Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is planned to include 40 patients with HER2-negative advanced breast cancer to receive fluzoparib combined with chidamide or fluzoparib combined with camrelizumab to observe and evaluate the efficacy and safety of fluzoparib combined with camrelizumab or chidamide in the treatment of HRD-positive HER2-negative advanced breast cancer.

Timeline

Start
2021-02-08
Primary completion
2023-10-31
Completion
2024-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Camrelizumab Monoclonal antibody 200 mg Intravenous
Subject Fluzoparib Small molecule 150 mg —
Subject Tucidinostat Small molecule 20 mg Oral

Indications

Her2-receptor negative breast cancer